Education
About Us
Working with TipRanks
Follow Us
Editas Medicine Inc. (EDIT)
:EDIT
EDIT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.12 - $7.60
Previous CloseN/A
Volume963.61K
Average Volume (3M)5.60M
Market Cap
$108.70M
Enterprise Value$54.67M
Total Cash (Recent Filing)$131.54M
Total Debt (Recent Filing)$35.03M
Price to Earnings (P/E)―
Beta1.86
Next Earnings
Apr 30, 2025EPS Estimate
-0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.88
Shares Outstanding82,976,280
10 Day Avg. Volume2,159,297
30 Day Avg. Volume5,600,624
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.36
Price to Cash Flow (P/CF)-0.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.50
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.69
Enterprise Value/Ebitda-0.24
Forecast
1Y Price Target
$3.14Price Target Upside139.69% Upside
Rating ConsensusHold
Number of Analyst Covering9
---
Editas Medicine News
PremiumCompany Announcements
Editas Medicine Announces CFO Transition
---
Bulls Say, Bears Say
Bulls Say
Development StrategyEditas is on track to potentially be the first company to advance an in vivo HSC-targeted therapy into the clinic.
Preclinical DataThe in vivo HSC sickle cell disease program has demonstrated encouraging preclinical data.
Bears Say
Competitive LandscapeInvestors are waiting for human proof-of-concept before committing, especially as the competitive landscape for in vivo programs intensifies with companies like Beam and CRISPR entering the space.
Human Proof-of-ConceptInvestors are awaiting human proof-of-concept before buying in, especially given that the in vivo competitive landscape continues to heat up.
Workforce ReductionA 65% reduction in force reflects the company's reprioritization efforts, which also led to the discontinuation of the reni-cel program as a commercial search failed to yield a partner.
---
Ownership Overview
0.82% Insiders
14.95% Mutual Funds
6.53% Other Institutional Investors
64.99% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
EDIT FAQ
What was Editas Medicine Inc.’s price range in the past 12 months?
Editas Medicine Inc. lowest stock price was $1.12 and its highest was $7.59 in the past 12 months.
What is Editas Medicine Inc.’s market cap?
Editas Medicine Inc.’s market cap is $108.70M.
When is Editas Medicine Inc.’s upcoming earnings report date?
Editas Medicine Inc.’s upcoming earnings report date is Apr 30, 2025 which is in 37 days.
How were Editas Medicine Inc.’s earnings last quarter?
Editas Medicine Inc. released its earnings results on Mar 05, 2025. The company reported -$0.55 earnings per share for the quarter, missing the consensus estimate of -$0.377 by -$0.173.
Is Editas Medicine Inc. overvalued?
According to Wall Street analysts Editas Medicine Inc.’s price is currently Undervalued.
Does Editas Medicine Inc. pay dividends?
Editas Medicine Inc. does not currently pay dividends.
What is Editas Medicine Inc.’s EPS estimate?
Editas Medicine Inc.’s EPS estimate is -0.56.
How many shares outstanding does Editas Medicine Inc. have?
Editas Medicine Inc. has 82,976,280 shares outstanding.
What happened to Editas Medicine Inc.’s price movement after its last earnings report?
Editas Medicine Inc. reported an EPS of -$0.55 in its last earnings report, missing expectations of -$0.377. Following the earnings report the stock price went down -13.171%.
Which hedge fund is a major shareholder of Editas Medicine Inc.?
Currently, no hedge funds are holding shares in EDIT
---
Editas Medicine Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$3.14 (139.69% Upside)
$3.14 (139.69% Upside)
Blogger Sentiment
Bullish
EDIT Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 176.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 6.1%
Last 30 Days ▼ 6.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-83.26%
12-Months-Change
Fundamentals
Return on Equity
-98.10%
Trailing 12-Months
Asset Growth
-31.57%
Trailing 12-Months
Company Description
Editas Medicine Inc.
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.
---
EDIT Stock 12 Month Forecast
Average Price Target
$3.14
▲(139.69% Upside)
Technical Analysis
Sangamo Biosciences
―
Bluebird Bio
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Beam Therapeutics
―
Best Analysts Covering EDIT
1 Year
1 Year Success Rate
6/16 ratings generated profit
1 Year Average Return
-9.31%
reiterated a buy rating 19 days ago
Copying Phil Nadeau's trades and holding each position for 1 Year would result in 37.50% of your transactions generating a profit, with an average return of -9.31% per trade.
---